1.
Ann Dermatol Venereol
; 136(5): 443-6, 2009 May.
Artigo
em Francês
| MEDLINE
| ID: mdl-19442803
RESUMO
INTRODUCTION: Bortezomid is a potent proteasome inhibitor used in patients with relapsing or refractory multiple myeloma and provides a 35% response with a median duration of response of 12 months. Numerous adverse effects are known, mainly comprising haematological and neurological complications. A wide variety of cutaneous complications have also been described in 10 to 20% of patients. CASE REPORT: We report a case of bortezomib-induced Sweet syndrome. The diagnostic criteria required for drug-induced Sweet syndrome were present. DISCUSSION: The importance of this description is that this induced Sweet syndrome may not necessarily require cessation of bortezomid since administration of corticosteroids prevents its recurrence.
Assuntos
Antineoplásicos/efeitos adversos , Ácidos Borônicos/efeitos adversos , Mieloma Múltiplo/tratamento farmacológico , Neutrófilos/patologia , Pirazinas/efeitos adversos , Dermatopatias/induzido quimicamente , Dermatopatias/patologia , Idoso , Antineoplásicos/uso terapêutico , Apoptose/efeitos dos fármacos , Ácidos Borônicos/uso terapêutico , Bortezomib , Humanos , Masculino , Neutrófilos/efeitos dos fármacos , Pirazinas/uso terapêutico , Síndrome de Sweet/induzido quimicamente , Síndrome de Sweet/patologia
2.
Pathology
; 51(3): 331-334, 2019 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30837084